Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518229

— · C

b890885a-c6ba-57eb-956b-8f1037e7446c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.350
  • PEROXISOME+0.320
  • FATTY_ACID_METABOLISM+0.280
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
  • APICAL_JUNCTION+0.230
  • ANGIOGENESIS+0.220
  • COAGULATION+0.210
  • APOPTOSIS+0.180
  • BILE_ACID_METABOLISM+0.160
  • ADIPOGENESIS+0.150

Top 10 suppressed

  • MYC_TARGETS_V2-0.520
  • MYC_TARGETS_V1-0.380
  • E2F_TARGETS-0.320
  • G2M_CHECKPOINT-0.260
  • WNT_BETA_CATENIN_SIGNALING-0.250
  • UNFOLDED_PROTEIN_RESPONSE-0.240
  • IL6_JAK_STAT3_SIGNALING-0.230
  • TNFA_SIGNALING_VIA_NFKB-0.210
  • INTERFERON_GAMMA_RESPONSE-0.190
  • ALLOGRAFT_REJECTION-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518146
breast-umap@18
—F0.811
2C3N-02088
lung-landscapes@6
—cohortA10.782
3TCGA-05-5715-01A-01R-1628-07
lung-landscapes@6
—cohortA10.781
4SRR8613754
breast-umap@18
—F0.778
5TCGA-A7-A0DB-01A-11R-A00Z-07
breast-umap@18
—A0.757
6MNG260
mng-umap@100
——0.755
7GSM6454744
breast-umap@18
—A0.743
8SRR8518340
breast-umap@18
—F0.735
9TCGA-FD-A3SM-01A-11R-A22U-07
bladder-landscape@3
——0.734
10TCGA-38-4628-01A-01R-1206-07
lung-landscapes@6
—cohortA10.733

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.350Remibrutinib— uncovered
PEROXISOME0.320Idelalisib— uncovered
FATTY_ACID_METABOLISM0.280Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.270Inavolisib— uncovered
APICAL_JUNCTION0.230Inavolisib— uncovered
ANGIOGENESIS0.220Remibrutinib— uncovered
COAGULATION0.210Binimetinib— uncovered
APOPTOSIS0.180Idelalisib— uncovered
BILE_ACID_METABOLISM0.160Inavolisib— uncovered
ADIPOGENESIS0.150Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.150Inavolisib— uncovered
NOTCH_SIGNALING0.140Inavolisib— uncovered
TGF_BETA_SIGNALING0.130Inavolisib— uncovered
APICAL_SURFACE0.120Temsirolimus— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
PROTEIN_SECRETION0.080Remibrutinib— uncovered
MYOGENESIS0.070Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.070Remibrutinib— uncovered
P53_PATHWAY0.070Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.030Inavolisib— uncovered